GradientScreen Microfluidic Platform Screens Three-Drug Ratios for Pediatric Acute Lymphoblastic Leukemia in Three Days

The GradientScreen microfluidic platform, developed by Wilbur A. Lam's group at Georgia Institute of Technology and Emory University, screens three-drug combination ratios for pediatric acute lymphoblastic leukemia in three days. The platform uses a microfluidic device to generate overlapping drug gradients and characterizes overall efficacy (Emax), potency synergy, and efficacy synergy of three-drug combinations in a ratio-dependent manner. With limited samples, the method achieves stable ratio-defined three-drug exposure for drug response screening in relapsed or refractory patients.